New combo therapy for breast cancer aims to improve outcomes without extra harm
NCT ID NCT07446686
First seen Mar 10, 2026 · Last updated Apr 28, 2026 · Updated 4 times
Summary
This early-stage study tests whether adding a targeted drug (CDK4/6 inhibitor) to standard radiation after surgery is safe and tolerable for women with a common type of high-risk breast cancer (HR+/HER2-). About 30 participants will receive the combination, and researchers will monitor side effects and quality of life. The goal is to find a dose that controls the disease without causing severe problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.